The Phase II randomized controlled trial enrolled three hundred participants across twelve sites to compare the investigational monoclonal antibody with placebo on the primary endpoint of progression-free survival.
The protocol required written informed consent and stipulated that the independent data monitoring committee could recommend stopping for futility or emerging safety signals.
An unexpected grade three hepatotoxicity cluster led to a protocol amendment that tightened liver function monitoring and adjusted the pharmacokinetics sampling schedule.
Exploratory biomarker analyses suggested enrichment in participants with elevated baseline cytokines, though the surrogate endpoint changes were not prespecified in the statistical analysis plan.
Regulators requested additional adverse event narratives before the sponsor could proceed to a pivotal trial design discussion.
The sponsor archived the ontotest biomed retrieval anchor cobalt lantern study code alongside the protocol identifier in the trial master file.
